Literature DB >> 8394069

Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens.

H G Heine1, D B Boyle.   

Abstract

Two fowlpox virus recombinants were constructed which expressed the host-protective antigen, VP2, of infectious bursal disease virus (IBDV). Recombinant FPV-VP 2.4.3 contained the gene for the VP 2-VP4-VP3 polyprotein under the control of the vaccinia virus late promoter P.L 11 inserted within the thymidine kinase (TK) gene of FPV. In infected chicken embryo skin (CES) cells VP2 and VP3 proteins were correctly processed from the polyprotein precursor molecule. Recombinant FPV-VP2 contained only the VP2 encoding region under the control of the fowlpox early/late promoter P.E/L inserted immediately downstream of the TK gene. The expression level of VP2 from FPV-VP2 was approximately 5 times higher than from FPV-VP2.4.3. Wing web inoculation of birds resulted in the development of typical fowlpox lesions and the development of antibodies to FPV with either of the recombinants, but only birds vaccinated with FPV-VP2 developed antibodies to IBDV. When challenged with IBDV (strain 002-73), a significant level of protection was provided by FPV-VP2 vaccination, although the level was lower than the protection provided by an oil adjuvanted inactivated whole IBDV vaccine. Birds vaccinated with FPV-VP2.4.3 were not protected from infection as assessed by ELISA for the presence of IBD virus in bursae.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394069     DOI: 10.1007/bf01378632

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  31 in total

1.  Restriction endonuclease mapping of the fowlpox virus genome.

Authors:  B E Coupar; T Teo; D B Boyle
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

2.  Deletion mapping and expression in Escherichia coli of the large genomic segment of a birnavirus.

Authors:  A A Azad; M N Jagadish; M A Brown; P J Hudson
Journal:  Virology       Date:  1987-11       Impact factor: 3.616

3.  Differentiation of infectious bursal disease viruses directly from infected tissues with neutralizing monoclonal antibodies: evidence of a major antigenic shift in recent field isolates.

Authors:  D B Snyder; D P Lana; P K Savage; F S Yancey; S A Mengel; W W Marquardt
Journal:  Avian Dis       Date:  1988 Jul-Sep       Impact factor: 1.577

4.  Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype.

Authors:  R M Buller; G L Smith; K Cremer; A L Notkins; B Moss
Journal:  Nature       Date:  1985 Oct 31-Nov 6       Impact factor: 49.962

5.  Recombinant fowlpox viruses inducing protective immunity against Newcastle disease and fowlpox viruses.

Authors:  R Ogawa; N Yanagida; S Saeki; S Saito; S Ohkawa; H Gotoh; K Kodama; K Kamogawa; K Sawaguchi; Y Iritani
Journal:  Vaccine       Date:  1990-10       Impact factor: 3.641

6.  Genomic structure of the large RNA segment of infectious bursal disease virus.

Authors:  P J Hudson; N M McKern; B E Power; A A Azad
Journal:  Nucleic Acids Res       Date:  1986-06-25       Impact factor: 16.971

7.  A dominant selectable marker for the construction of recombinant poxviruses.

Authors:  D B Boyle; B E Coupar
Journal:  Gene       Date:  1988-05-15       Impact factor: 3.688

8.  Construction of recombinant fowlpox viruses as vectors for poultry vaccines.

Authors:  D B Boyle; B E Coupar
Journal:  Virus Res       Date:  1988-06       Impact factor: 3.303

9.  Sequence analysis and expression of the host-protective immunogen VP2 of a variant strain of infectious bursal disease virus which can circumvent vaccination with standard type I strains.

Authors:  H G Heine; M Haritou; P Failla; K Fahey; A Azad
Journal:  J Gen Virol       Date:  1991-08       Impact factor: 3.891

10.  The characterization and molecular cloning of the double-stranded RNA genome of an Australian strain of infectious bursal disease virus.

Authors:  A A Azad; S A Barrett; K J Fahey
Journal:  Virology       Date:  1985-05       Impact factor: 3.616

View more
  19 in total

1.  Development of an effective polyvalent vaccine against both Marek's and Newcastle diseases based on recombinant Marek's disease virus type 1 in commercial chickens with maternal antibodies.

Authors:  K Sonoda; M Sakaguchi; H Okamura; K Yokogawa; E Tokunaga; S Tokiyoshi; Y Kawaguchi; K Hirai
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  The major antigenic protein of infectious bursal disease virus, VP2, is an apoptotic inducer.

Authors:  A Fernández-Arias; S Martínez; J F Rodríguez
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 3.  Infectious bursal disease virus: a review of molecular basis for variations in antigenicity and virulence.

Authors:  M M Nagarajan; F S Kibenge
Journal:  Can J Vet Res       Date:  1997-04       Impact factor: 1.310

4.  Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus.

Authors:  K H Leong; A J Ramsay; D B Boyle; I A Ramshaw
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

5.  Complete, long-lasting protection against lethal infectious bursal disease virus challenge by a single vaccination with an avian herpesvirus vector expressing VP2 antigens.

Authors:  K Tsukamoto; S Saito; S Saeki; T Sato; N Tanimura; T Isobe; M Mase; T Imada; N Yuasa; S Yamaguchi
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV.

Authors:  Zhuhui Huang; Subbiah Elankumaran; Abdul S Yunus; Siba K Samal
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

7.  Expression of VP2 gene protein of infectious bursal disease virus detected in Korea.

Authors:  Toh-Kyung Kim; Sang-Geon Yeo
Journal:  Virus Genes       Date:  2003-08       Impact factor: 2.332

8.  The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity In vivo.

Authors:  S Mahalingam; J M Farber; G Karupiah
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  Vaccination with E. coli recombinant empty viral particles of infectious bursal disease virus (IBDV) confer protection.

Authors:  Arie Rogel; Luna Benvenisti; Ilan Sela; Orit Edelbaum; Edna Tanne; Yehoshua Shachar; Yehuda Zanberg; Tanya Gontmakher; Eli Khayat; Yehuda Stram
Journal:  Virus Genes       Date:  2003-10       Impact factor: 2.332

10.  Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus.

Authors:  S J Kent; A Zhao; S J Best; J D Chandler; D B Boyle; I A Ramshaw
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.